The company reported a 72% decline in revenue from the RSV vaccine. Meanwhile, rival Pfizer said its RSV vaccine sales fell just 5%.
GSK Takes a Dive as Vaccine Sales Fall Short
Related Posts
Empower your financial future with knowledge and awareness